リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma

平木 洋子 近畿大学

2022.02.28

概要

Purpose.
The purpose of this study is to determine the clinical significance of micrometastases after neoadjuvant chemotherapy （NAC） and the difference in controlling micrometastases using different NAC regimens in resectable advanced esophageal squamous cell carcinoma （ESCC）.

Methods.
We analyzed patients with ESCC who underwent esophagectomy with lymph node dissection after NAC with Adriamycin + cisplatin + 5-fluorouracil （ACF） or docetaxel + cisplatin + 5-fluorouracil （DCF）. Micrometastasis was defined as a single isolated cancer cell or cluster of cancer cells on the cervical, recurrent nerve, or abdominal LNs as shown by immunohistochemical staining with anti-cytokeratin antibody （AE1/AE3）. The associations between micrometastases, recurrence, prognosis, and regimen differences were investigated.

Results.
One hundred and one cases （ACF group: 51 cases; DCF group: 50 cases） were analyzed. Micrometastases occurred in 24 patients （23.8%）: 17/51 （33.3%） in the ACF group and 7/50 （13.5%） in the DCF group （P=0.0403）. The 5-year recurrence-free survival （RFS） rates for patients without （n=77） and with （n=24） micrometastases were 62% and 32%, respectively （hazard ratio, 2.158; 95% confidence interval, 1.170–3.980; stratified log-rank test, P=0.0115）. A multivariate analysis showed that stage pN1 or higher and micrometastases were significant risk factors affecting RFS.

Conclusion.
In resectable advanced ESCC, controlling micrometastases in the LNs after NAC varied by regimen and may be associated with preventing ESCC recurrence.

Keywords：esophageal squamous cell carcinoma, neoadjuvant chemotherapy, micrometastases

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

１．Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979-84.

２．van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84.

３．Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis. Lancet Oncol. 2011;12:681-92.

４．Mayanagi S, Irino T, Kawakubo H, Kitagawa Y. Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. Ann Gastroenterol Surg. 2019;3:269-75.

５．Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society:part 1. Esophagus. 2019;16:1-24.

６．Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus （JCOG9907）. Ann Surg Oncol. 2012;19:68-74.

７．Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062-7.

８．Yamasaki M, Miyata H, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, et al. Perioperative therapy for esophageal cancer. Gen Thorac Cardiovasc Surg. 2014;62:531-40.

９．Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, et al. Comprehensive registry of esophageal cancer in Japan, 2011. Esophagus. 2018;15:127-52.

１０．Motoori M, Yano M, Yasuda T, Miyata H, Peng YF, Yamasaki M, et al. Chemotherapy-induced toxicities and treatment efficacy in advanced esophageal cancer treated with neoadjuvant chemotherapy followed by surgery. Esophagus. 2011;8:81-7.

１１．Shimakawa T, Naritaka Y, Asaka S, Isohata N, Murayama M, Konno S, et al. Neoadjuvant chemotherapy （FAP） for advanced esophageal cancer. Anticancer Res. 2008;28:2321-6.

１２．Tamura S, Takeno A, Taniguchi H, Katsura Y, Ohmura Y, Kagawa Y, et al. Induction chemotherapy using FAP for patients with Stage II/III squamous cell carcinoma of the esophagus. Anticancer Res. 2015;35:2975-82.

１３．Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF, et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011 ;80:307-13.

１４．Shiraishi O, Yamasaki M, Makino T, Motoori M, Miyata H, Shinkai M, et al. Feasibility of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil versus Adriamycin, cisplatin, and 5-fluorouracil for resectable advanced esophageal cancer. Oncology. 2017;92:101-8.

１５．Yamasaki M, Yasuda T, Yano M, Hirao M, Kobayashi K, Fujitani K, et al. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel （DCF） compared with cisplatin and fluorouracil plus Adriamycin （ACF） as preoperative chemotherapy for resectable esophageal squamous cell carcinoma （OGSG1003）. Ann Oncol. 2017;28:116-20.

１６．Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997;337:1188-94.

１７．Doki Y, Ishikawa O, Mano M, Hiratsuka M, Sasaki Y, Kameyama M, et al. Cytokeratin deposits in lymph nodes show distinct clinical significance from lymph node micrometastasis in human esophageal cancers. J Surg Res. 2002;107:75-81.

１８．Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors, 8th edition. Oxford:Wiley-Blackwell 2017.

１９．Japanese Society for Esophageal Diseases:Guideline for clinical and pathological studies on carcinoma of the esophagus, ninth edition:part II. Esophagus. 2004;1:107-25.

２０．Tachimori Y, Ozawa S, Numasaki H, Matsubara H, Shinoda M, Toh Y, et al. Efficacy of lymph node dissection by node zones according to tumor location for esophageal squamous cell carcinoma. Esophagus. 2016;13:138-45.

２１．Komukai S, Nishimaki T, Watanabe H, jioka Y, Suzuki T, Hatakeyama K. Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. Surgery. 2000;127:40-6.

２２．Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol. 2003;21:4592-6.

２３．MacGuill MJ, Barrett C, Ravi N, MacDonald G, Reynolds JV. Isolated tumour cells in pathological node-negative lymph nodes adversely affect prognosis in cancer of the oesophagus or oesophagogastric junction. J Clin Pathol. 2007;60:1108-11.

２４．Prenzel KL, Hölscher AH, Drebber U, Agavonova M, Gutschow CA, Bollschweiler E. Prognostic impact of nodal micrometastasis in early esophageal cancer. Eur J Surg Oncol. 2012;38:314-8.

２５．Prenzel KL, König A, Schneider PM, Schnickmann C, Baldus SE, Schröder W, et al. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. Ann Surg Oncol. 2007;14:954-9.

２６．Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer:final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014;32:2416-22.

２７．Yanagi M, Sasaki K, Uchikado Y, Omoto I, Arigami T, Kurahara H, et al. Effect of neoadjuvant chemoradiotherapy on lymph node micrometastases in thoracic esophageal cancer. Anticancer Res. 2018;38:893-900.

２８．Robb WB, Messager M, Dahan L, Mornex F, Maillard E, D’Journo XB, et al. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone. Br J Surg. 2016;103:117-25.

２９．Oppedijk V, van der Gaast A, van Lanschot JJ, van Hagen P, van Os R, van Rij CM, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32:385-91.

３０．Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol. 2016;27:660-7.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る